`
` dmbmd@retinaconsultantstexas.com
`www.retinaconsultantstexas.com
`Academic Administrator: Madison Tebo
`dmbadmin@retinaconsultantstexas.com
`Phone: 713‐394‐7520
`
`Retina Consultants of Texas, an RCA Company
`Physician Partner & Director of Research
`1995‐Present
`
`Newcastle Office (Main Office & Research Office)
`4460 Bissonnet Street, Suite 200, Bellaire, Texas 77401
`
`The Woodlands Office (Research Office)
`17350 St. Luke’s Way, Suite 120, The Woodlands, Texas 77384
`Kingwood Office (Research Office)
`350 Kingwood Medical Drive, Suite 200, Kingwood, Texas 77339
`
`Katy Office (Research Office)
`23501 Cinco Ranch Boulevard, Suite G205, Katy, TX 77494
`
`Memorial Office (Research Office)
`10100 Katy Freeway, Suite 100, Houston, TX 77043
`
`Peakwood Office (Research Office)
`800 Peakwood Drive, Suite 1C, Houston, TX 77090
`
`Sugar Land Office (Research Office)
`6921 Brisbane Court, Suite 200, Sugar Land, TX 77479
`
`Space Center/Pasadena
`11460 Space Center Boulevard., Suite 2, Houston, TX 77059
`
`Northwest Office
`21216 NW Freeway, Suite 630, Cypress, TX 77429
`
`Brenham TX Office
`2620 Hwy 36 South, Brenham, TX 77833
`
`Lufkin TX Office
`2906 Brentwood Drive, Suite 300, Lufkin, TX 75901
`San Antonio TX Offices (Research offices)
`9480 Huebner Road, Suite 310, San Antonio, TX 78240
`10439 State Highway 151, San Antonio, TX 78251
`
`Beaumont TX Office (Research Office)
`87 Interstate North, Suite 103, Beaumont, TX 77707
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 1
`
`
`
`BOARD CERTIFICATION
`Diplomat, American Board of Ophthalmology 1994
`ABO Recertification (2005‐2014) & (2015‐2024)
`LICENSURE
`Texas License #H5425
`DEA#: BB1702213
`EDUCATION & TRAINING
`1993‐1995 University of Iowa Hospitals & Clinics
`Medical Retina & Vitreoretinal Surgery Fellowship
`1990‐1993 University of Iowa Hospitals & Clinics
`Ophthalmology Residency
`1989‐1990 Baylor College of Medicine
`Medical/Surgical Internship
`1984‐1988 Baylor College of Medicine
`Doctorate of Medicine with “High Honors
`1981‐1984 Houston Baptist University
`Bachelor of Science summa cum laude (4.0/4.0 GPA)
`ACADEMIC APPOINTMENTS
`Clinical Professor of Ophthalmology, Department of Ophthalmology
`Baylor College of Medicine, Houston, Texas
`Vice‐Chair of Ophthalmology for Research, Department of Ophthalmology,
`The Methodist Hospital, Weill Cornell College of Medicine, Houston, Texas
`Associate Clinical Professor of Ophthalmology, The Methodist Hospital,
`Weill Cornell Medical College, Houston, Texas
`NASA‐ Research and Clinical Advisory Panel‐Space Associated Neuro‐ophthalmic Syndrome
`NASA Johnson Space Center, Houston, Texas
`ACADEMIC & RESEARCH HONORS
`American Society of Retina Specialists (ASRS) Presidential Honor Award 2023
`American Academy of Ophthalmology Senior Achievement Award 2014
`American Society of Retina Specialists (ASRS) Senior Honor Award 2010
`American Society of Retina Specialists (ASRS) Honor Award 2008
`Academy of Ophthalmology Honor Award 2000
`Heed‐Knapp Ophthalmic Foundation Fellowship 1994‐1995
`Ronald G. Michels Foundation Fellowship Award 1994
`(presented to most outstanding U.S. Retina fellow)
`Heed Ophthalmic Foundation Thomas Heed Fellowship 1993‐1994
`PJ Leinfelder Award (most outstanding research in residency) 1991‐1992
`ELECTED HONORARY SOCIETIES & LISTS
`Club Jules Gonin Society (2018)
`RETINA HALL OF FAME (charter inductee‐ 2017)
`
`David M. Brown MD FACS
`Page 2
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 2
`
`
`
`Texas Monthly “Super Doc” (2009‐2023)
`“Best Doctors In America” (2007‐2023)
`Macula Society (2008‐present)
`Retina Society (2006‐present)
`Ronald G. Michels Fellowship Society (1994)
`Society of Thomas Heed Fellows (1993)
`Alpha Omega Alpha Medical Honor Society (1985)
`PROFESSIONAL ORGANIZATIONS & SOCIETIES
`Fellow, American Academy of Ophthalmology
`Diplomate, American Board of Ophthalmology
`Harris County Ophthalmology Society
`Harris County Medical Society
`Iowa Eye Association
`Fellow, American College of Surgeons
`Association for Research in Vision (ARVO)
`American Society of Retina Specialists
`American Society of Cataract & Refractive Surgery
`American Diabetes Association
`Juvenile Diabetes Research Foundation
`Texas Ophthalmologic Association
`American Medical Association
`PROFESSIONAL ORGANIZATIONS & SOCIETIES‐ LEADERSHIP ROLES
`Retina Society‐ Audit Committee Chair (2022‐present)
`American Society of Retina Specialists ‐ Board of Directors 2014‐2021
`American Society of Retina Specialists ‐ Practice Management Chair 2014‐17
`American Society of Retina Specialists – Governmental Affairs 2017‐2020
`The Foundation of the ASRS‐ Board of Directors 2014‐2021
`Macula Society ‐ Credentials Committee 2013‐2017
`Retina Society‐ Chair, Audit Committee‐ 2022‐ present
`Retina Society‐ Finance Committee‐ 2018‐2020
`Retina Society ‐ Nominating Committee Chairman 2013‐15
`Retina Society ‐ Nominating Committee 2011‐15
`American Society of Cataract & Refractive Surgery‐ Retina Clinical Committee 2015‐present
`Methodist Research Institute ‐ Internal Advisory Committee 2004‐2012
`Diabetic Retinopathy Clinical Research Network ‐ Executive Committee 2005‐2007
`Diabetic Research Clinical Network (DRCR) ‐ Planning Committee 2004‐2005
`Methodist Hospital Research Institute SPRINT ‐ Planning Committee 2003‐2004
`Harris County Ophthalmology Society ‐ President 2002‐2003
`Harris County Ophthalmology Society ‐ Executive Committee 1997‐2003
`Iowa Eye Association ‐ President 2002‐2003
`University of Iowa Center for Macular Degeneration ‐ Advisory Board 2003‐present
`Juvenile Diabetes Research Foundation ‐ Board of Directors 1998‐2002
`Houston American Diabetes Association ‐ Medical Advisory Board 2000‐2002
`Houston Area American Diabetes Association ‐ Board of Directors 1998‐2001
`
`David M. Brown MD FACS
`Page 3
`
`Page 03 of 48
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 3
`
`
`
`PEER REVIEWER
`American Journal of Ophthalmology
`Archives of Ophthalmology
`British Journal of Ophthalmology
`EYE
`New England Journal of Medicine
`OPHTHALMOLOGY
`RETINA, The Journal of Retina & Vitreous Diseases
`RETINA, Cases & Brief Reports
`
`GOOGLE SCHOLAR | EXPERTSCAPE RANKINGS
`h‐Index: 45
` i10 Index: 74
` Citations: 21,892
`Expertscape rankings: ‐based on Pubmed publications past 10 years (www.expertscape.com)
`Retinal Vein Occlusion: #3 worldwide, #1 Texas
`Macular Degeneration: #13 worldwide, #5 US, #1 Texas
`Diabetic Retinopathy: Top 30 worldwide, #1 Texas
`PUB‐MED INDEXED ORIGINAL PAPERS‐ AUTHOR
`
`‐Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S,
`Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators Effect of High‐Dose Intravitreal Aflibercept,
`8 mg, in Patients With Neovascular Age‐Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical
`Trial..JAMA Ophthalmol. 2023 Sep 1;141(9):834‐842 PMID: 37535382
`
`‐Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, Agostini HT, Chang A, Laude A, Wachtlin J, Kovacic L, Wang L,
`Wang Y, Bouillaud E, Brown DM. KESTREL and KITE Phase 3 studies: 100‐week results with brolucizumab in patients with
`diabetic macular edema. Am J Ophthalmol. 2023 Jul 15:S0002‐9394. PMID: 37460036
`
`‐Peng ET, Parvus MN, Yu HJ, Laswell SM, Pearce WA, Fan KC, Major JC Jr, Brown DM, Wykoff CC, Patel SB. Risk Factors for
`the Development of Fellow Eye Horseshoe Retinal Tears Following Horseshoe Retinal Tear in the Presenting Eye.
`Ophthalmic Surg Lasers Imaging Retina. 2023 Jun;54(6):338‐345 PMID: 37352399
`
`‐Heier JS, Ho AC, Boyer DS, Csaky K, Vitti R, Perlee L, Chu KW, Asmus F, Leal S, Zeitz O, Cheng Y, Schmelter T, Brown DM.
`Intravitreal Nesvacumab (Anti‐Angiopoietin‐2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.J
`Vitreoretin Dis. 2022 Dec 30;7(1):8‐15. PMID: 37008402
`
`‐Gibson CR, Mader TH, Lipsky W, Brown DM, Jennings R, Law J, Sargsyan A, Brunstetter T, Danilichev SN, Maezawa Y.
`Implantable Collamer Lens Use in a Spaceflight Participant During Short Duration Spaceflight. Aerosp Med Hum Perform.
`2023 Jan 1;94(1):48‐50. doi: 10.3357/AMHP.6150.2023. PMID: 36757221.
`‐Brown DM, Nowik M, Bouillaud E, Dugel APU; HAWK Extension Study Investigators. HAWK Extension Study: Safety and
`Efficacy of Intravitreal Brolucizumab in Neovascular Age‐related Macular Degeneration. Curr Eye Res. 2023 Jan;48(1):44‐50.
`doi: 10.1080/02713683.2022.2096907. Epub 2022 Nov 18. PMID: 36398628.
`‐Rao AV, Shah AR, Nguyen VT, Pearce W, Wong TP, Brown DM, Wykoff CC, Patel SB. Use of Optical Coherence Tomography
`in Acute, Symptomatic Posterior Vitreous Detachment. Retina. 2022 Dec 26. doi:
`in Detecting Retinal Tears
`10.1097/IAE.0000000000003718. Epub ahead of print. PMID: 36728866.
`
`David M. Brown MD FACS
`Page 4
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 4
`
`
`
`‐Eichenbaum D, Brown DM, Ip M, Khanani AM, Figueroa MS, McAllister IL, Laude A, Guruprasad B, Tang S, Gmeiner B, Clemens
`A, Souied E. Impact of retinal fluid‐free months on outcomes in nAMD: a treatment agnostic analysis of the HAWK and
`HARRIER studies. Retina. 2022 Dec 20. doi: 10.1097/IAE.0000000000003699. Epub ahead of print. PMID: 36705252.
`‐Brown DM, Kowalski MA, Paulus QM, Yu J, Kumar P, Kane MA, Patel JM, Ethier CR, Pardue MT. Altered Structure and Function
`of Murine Sclera in Form‐ Deprivation Myopia. Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):13. doi: 10.1167/iovs.63.13.13.
`PMID: 36512347; PMCID: PMC9753793.
`‐Hanna R, Brown DM, Brown A, Baldwin K. Measuring atmospheric turbulence along folded paths using a laser‐illuminated
`differential image motion monitor. Appl Opt. 2022 Nov 10;61(32):9646‐9653. doi: 10.1364/AO.468597. PMID: 36606905.
`‐Abraham JR, Wykoff CC, Arepalli S, Lunasco L, Yu HJ, Martin A, Mugnaini C, Hu M, Reese J, Srivastava SK, Brown DM, Ehlers
`JP. Exploring the angiographic‐ biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression. Br J
`Ophthalmol. 2022 Oct;106(10):1444‐1449. doi: 10.1136/bjophthalmol‐2020‐318726. Epub 2021 Jun 7. PMID: 34099465;
`PMCID: PMC8761372.
`‐Fan W, Fleming A, Hemert JV, Wykoff CC, Brown DM, Robertson G, Wang K, Falavarjani KG, Sadda SR, Ip M. RETINAL
`VASCULAR BED AREA IN EYES WITH RETINAL VEIN OCCLUSION ON ULTRA‐WIDEFIELD FLUORESCEIN ANGIOGRAPHY: WAVE
`Study. Retina. 2022 Oct 1;42(10):1883‐1888. doi: 10.1097/IAE.0000000000003549. PMID: 35976232.
`‐Khanani AM, Brown DM, Jaffe GJ, Wykoff CC, Adiguzel E, Wong R, Meng X, Heier JS; MERLIN Investigators. MERLIN: Phase
`3a, Multicenter, Randomized, Double‐ Masked Trial of Brolucizumab in Participants with Neovascular Age‐Related Macular
`Degeneration and Persistent Retinal Fluid. Ophthalmology. 2022 Sep;129(9):974‐985. doi: 10.1016/j.ophtha.2022.04.028.
`Epub 2022 May 7. PMID: 35537533.
`‐Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, Wolf S, Gupta V, Ngah NF, Liew G, Tuli R, Tadayoni R,
`Dhoot D, Wang L, Bouillaud E, Wang Y, Kovacic L, Guerard N, Garweg JG. KESTREL and KITE: 52‐Week Results From Two Phase
`III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022 Jun; 238:157‐172. doi:
`10.1016/j.ajo.2022.01.004. Epub 2022 Jan 14. PMID: 35038415.
`‐Brown DM, Boyer DS, Csaky K, Vitti R, Perlee L, Chu KW, Asmus F, Leal S, Zeitz O, Cheng Y, Schmelter T, Heier JS; RUBY
`Investigators. INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase
`2 RUBY Randomized Trial. Retina. 2022 Jun 1;42(6):1111‐1120. doi: 10.1097/IAE.0000000000003441. Epub 2022 Feb 22.
`PMID: 35234673; PMCID: PMC9112959.
`‐Ehlers JP, Patel N, Kaiser PK, Heier JS, Brown DM, Meng X, Reese J, Lunasco L, Le TK, Hu M, Srivastava SK. The Association of
`Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD. Invest Ophthalmol
`Vis Sci. 2022 Jun 1;63(6):17. doi: 10.1167/iovs.63.6.17. PMID: 35713892; PMCID: PMC9206498.
`‐Fan W, Uji A, Wykoff CC, Brown DM, van Hemert J, Falavarjani KG, Wang K, Sadda SR, Ip M. Baseline retinal vascular bed
`area on ultra‐wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to
`ranibizumab therapy: two‐year analysis of the DAVE Study. Eye (Lond). 2022 Mar 24. doi: 10.1038/s41433‐021‐01777‐7. Epub
`ahead of print. PMID: 35332289.
`‐Fan W, Nittala MG, Wykoff CC, Brown DM, Uji A, Hemert JV, Fleming A, Robertson G, Sadda SR, Ip M. NEW BIOMARKER
`QUANTIFYING THE EFFECT OF ANTI‐VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE
`Retina.
`doi:
`1;42(3):426‐433.
`FIELD
`FLUORESCEIN
`ANGIOGRAPHY:
`RECOVERY
`Study.
`2022 Mar
`10.1097/IAE.0000000000003358. PMID: 34803132.
`‐Kar SS, Abraham J, Wykoff CC, Sevgi DD, Lunasco L, Brown DM, Srivastava SK, Madabhushi A, Ehlers JP. Computational
`Imaging Biomarker Correlation with Intraocular Cytokine Expression in Diabetic Macular Edema: Radiomics Insights from the
`IMAGINE Study. Ophthalmol Sci. 2022 Feb 4;2(2):100123. doi: 10.1016/j.xops.2022.100123. PMID: 36249694; PMCID:
`PMC9560558.
`‐Brown DM, Hanna RT, Brown AM, Hixson JG, Baldwin KC. Numerical simulation of a large area scintillometer and laser
`differential image motion monitor. Appl Opt. 2022 Jan 1;61(1):10‐21. doi: 10.1364/AO.442064. PMID: 35200796.
`
`David M. Brown MD FACS
`Page 5
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 5
`
`
`
`‐Brown DM. Reply. Ophthalmology. 2021 Oct;128(10): e70. doi: 10.1016/j.ophtha.2021.03.039. Epub 2021 May 13. PMID:
`33992472.
`‐Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD,
`Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative
`Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 1;139(9):946‐
`955. doi: 10.1001/jamaophthalmol.2021.2809. PMID: 34351414; PMCID: PMC8343518.
`
`‐Spaide RF, Gemmy Cheung CM, Matsumoto H, Kishi S, Boon CJF, van Dijk EHC, Mauget‐Faysse M, Behar‐Cohen F, Hartnett
`ME, Sivaprasad S, Iida T, Brown DM, Chhablani J, Maloca PM. Venous overload choroidopathy: A hypothetical framework for
`serous chorioretinopathy and allied disorders. Prog Retin Eye Res. 2022
`Jan;86:100973. doi:
`central
`10.1016/j.preteyeres.2021.100973. Epub 2021 May 21. PMID: 34029721.
`‐Heier JS, Brown DM, Shah SP, Saroj N, Dang S, Waheed NK, Wykoff CC, Prenner JL, Boyer DS. Intravitreal Aflibercept Injection
`vs Sham as Prophylaxis Against Conversion to Exudative Age‐Related Macular Degeneration in High‐risk Eyes: A Randomized
`Clinical Trial. JAMA Ophthalmol. 2021 May 1;139(5):542‐547. doi: 10.1001/jamaophthalmol.2021.0221. PMID: 33734306;
`PMCID: PMC7974836.
`‐Ehlers JP, Zahid R, Kaiser PK, Heier JS, Brown DM, Meng X, Reese J, Le TK, Lunasco L, Hu M, Srivastava SK. Longitudinal
`Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in
`Neovascular Age‐Related Macular Degeneration. Ophthalmol
`Retina.
`2021 Dec;5(12):1204‐1213.
`doi:
`10.1016/j.oret.2021.02.012. Epub 2021 Feb 26. PMID: 33640493; PMCID: PMC8387490.
`‐Abraham JR, Wykoff CC, Arepalli S, Lunasco L, Yu HJ, Hu M, Reese J, Srivastava SK, Brown DM, Ehlers JP. Aqueous Cytokine
`Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic‐Biologic Bridge in the IMAGINE DME Study. Am J
`Ophthalmol. 2020 Sep 5; 222:328‐339. PMID: 32896498.
`‐Fan W, Uji A, Wang K, Falavarjani KG, Wykoff CC, Brown DM, Van Hemert J, Sagong M, Sadda SR, Ip M. Severity of Diabetic
`Macular Edema Correlates with Retinal Vascular Bed Area on Ultra‐Wide Field Fluorescein Angiography: DAVE Study. Retina.
`2020 Jun;40(6):1029‐1037 PMID: 31356494.
`‐Yu HJ, Kaiser PK, Zamora D, Bocanegra M, Cone C, Brown DM, Sadda SR, Wykoff CC. Visual Acuity Variability: Comparing
`Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. Ophthalmol Retina.
`2020 Apr 23: S2468‐6530(20)30154‐8. PMID: 32595096.
`‐Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX‐DME Study Group. Long‐term outcomes of treat‐and‐
`extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX‐DME 3‐year results. Br J
`Ophthalmol. 2020 Apr 17: bjophthalmol‐2020‐316176. PMID: 32303499.
`‐Major JC Jr, Lampen SIR, Wykoff CC, Ou WC, Brown DM, Wong TP, Shah AR. The Texas Taco Technique For Internal Limiting
`Membrane Flap In Large Full‐Thickness Macular Holes: A Short‐Term Pilot Study. Retina. 2020 Mar;40(3):552 556. PMID:
`30608347.
`‐Zhou B, Mitchell TC, Rusakevich AM, Brown DM, Wykoff CC. Noncompliance in Prospective Retina Clinical Trials: Analysis of
`Factors Predicting Loss to Follow‐up. Am J Ophthalmol. 2020 Feb; 210:86‐96. Epub 2019 Oct 21. PMID: 31647931.
`‐Heier JS, Wykoff CC, Waheed NK, Kitchens JW, Patel SS, Vitti R, Perlee L, Chu KW, Leal S, Asmus F, Son V, Schmelter T, Brown
`DM. Intravitreal Combined Aflibercept + Anti‐Platelet‐Derived Growth Factor Receptor β for Neovascular Age‐Related
`Macular Degeneration: Results of the Phase 2 CAPELLA Trial. Ophthalmology. 2020 Feb;127(2):211‐220. Epub 2019 Sep 25.
`PMID: 31791663.
`‐Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F,
`Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS,
`Francois CG. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age‐Related Macular
`Degeneration: A Randomized Phase 2 Trial. Ophthalmology. 2020 Feb;127(2):186‐195. Epub 2019 Jul 16. PMID: 31474439.
`
`David M. Brown MD FACS
`Page 6
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 6
`
`
`
`‐Fan W, Nittala MG, Fleming A, Robertson G, Uji A, Wykoff CC, Brown DM, van Hemert J, Ip M, Wang K, Falavarjani KG, Singer
`M, Sagong M, Sadda SR. Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on
`Ultrawide‐Field Fluorescein Angiography. Am J Ophthalmol. 2020 Jan; 209:99‐106. Epub 2019 Aug 29. PMID: 31472160.
`‐Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt‐Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG;
`HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double Masked Trials of
`Brolucizumab for Neovascular Age‐Related Macular Degeneration. Ophthalmology. 2020 Jan;127(1):72‐84. Epub 2019 Apr
`12. PMID: 30986442.
`‐Wykoff CC, Nittala MG, Zhou B, Fan W, Velaga SB, Lampen SIR, Rusakevich AM, Ehlers JP, Babiuch A, Brown DM, Ip MS, Sadda
`SR; Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy Study Group. Intravitreal Aflibercept
`for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial. Ophthalmol
`Retina. 2019 Dec;3(12):1076‐1086. Epub 2019 Jul 24. PMID: 31542339.
`‐Ehlers JP, Uchida A, Hu M, Figueiredo N, Kaiser PK, Heier JS, Brown DM, Boyer DS, Do DV, Gibson A, Saroj N, Srivastava SK.
`Higher‐Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal
`Fluid Index. Ophthalmol Retina. 2019 Dec;3(12):1056‐1066. Epub 2019 Jul 6. PMID: 31473172.
`‐Fang M, Fan W, Shi Y, Ip MS, Wykoff CC, Wang K, Falavarjani KG, Brown DM, van Hemert J, Sadda SR. Classification of Regions
`of Nonperfusion on Ultra‐ widefield Fluorescein Angiography in Patients with Diabetic Macular Edema. Am J Ophthalmol.
`2019 Oct; 206:74‐81. Epub 2019 Apr 6. PMID: 30959003.
`‐Feltgen N, Ogura Y, Boscia F, Holz FG, Korobelnik JF, Brown DM, Heier JS, Stemper B, Rittenhouse KD, Asmus F, Ahlers C, Vitti
`R, Saroj N, Mitchell P. Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in
`the COPERNICUS and GALILEO Studies. Ophthalmol Retina. 2019 Jul;3(7):553‐560. Epub 2019 Feb 27. PMID: 31277796.
`‐Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX‐DME Study Group. Randomized Trial of Treat and
`Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX‐DME 2‐
`Year Outcomes. Am J Ophthalmol. 2019 Jun; 202:91‐99. Epub 2019 Feb 14. PMID: 30771333.
`‐Kim RS, Jain RR, Brown DM, Bretana ME, Kegley EN, Singer MA, Aragon AV, Schefler AC. Elevated Choroidal Thickness and
`Central Serous Chorioretinopathy in the Fellow Eyes of Patients with Circumscribed Choroidal Hemangioma. Ocul Oncol
`Pathol. 2018 Nov;4(6):375‐380. Epub 2018 Apr 20. PMID: 30574490.
`‐Mitchell P, McAllister I, Larsen M, Staurenghi G, Korobelnik JF, Boyer DS, Do DV, Brown DM, Katz TA, Berliner A, Vitti R, Zeitz
`O, Metzig C, Lu C, Holz FG. Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID‐
`DME and VISTA‐DME Studies. Ophthalmol Retina. 2018 Oct;2(10):988‐996. Epub 2018 Mar 31. PMID: 31047501.
`‐Lampen SIR, Khurana RN, Noronha G, Brown DM, Wykoff CC. Suprachoroidal Space Alterations Following Delivery of
`Triamcinolone Acetonide: Post‐Hoc Analysis of the Phase 1/2 HULK Study of Patients With Diabetic Macular Edema.
`Ophthalmic Surg Lasers Imaging Retina. 2018 Sep 1;49(9):692‐697. PMID: 30222804.
`‐Wykoff CC, Khurana RN, Lampen SIR, Noronha G, Brown DM, Ou WC, Sadda SR; HULK Study Group. Suprachoroidal
`Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial. Ophthalmol Retina. 2018 Aug;2(8):874‐877. Epub 2018
`May 4. PMID: 31047542.
`‐Kwon S, Wykoff CC, Brown DM, van Hemert J, Fan W, Sadda SR. Changes in retinal ischaemic index correlate with recalcitrant
`macular oedema in retinal vein occlusion: WAVE study. Br J Ophthalmol. 2018 Aug;102(8):1066‐1071. Epub 2018 Apr 26.
`PMID:29699979.
`‐Brown DM, Ou WC, Wong TP, Kim RY, Croft DE, Wykoff CC; DAVE Study Group. Targeted Retinal Photocoagulation for
`Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three‐Year Randomized DAVE Trial. Ophthalmology. 2018
`May;125(5):683‐690. PMID: 29336896.
`‐Payne JF, Clark WL, Bruce BB, Wykoff CC, Brown DM, Menke BM, Iverson SM, Allen KF, Boyer DS; Treat & Extend Protocol in
`Patients with Diabetic Macular Edema Study Group. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic
`Macular Edema. Ophthalmology. 2018 May 2. pii: S0161‐6420(18)30678‐X. PubMed PMID: 29729809.
`
`David M. Brown MD FACS
`Page 7
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 7
`
`
`
`‐Brown DM, Ou WC, Wong TP, Kim RY, Croft DE, Wykoff CC; DAVE Study Group. Targeted Retinal Photocoagulation for
`Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three‐Year Randomized DAVE Trial. Ophthalmology. 2018
`May;125(5):683‐690.PubMed PMID: 29336896.
`‐Wykoff CC, Ou WC, Khurana RN, Brown DM, Lloyd Clark W, Boyer DS; ENDURANCE Study Group. Long‐term outcomes with
`as‐needed aflibercept in diabetic macular edema: 2‐year outcomes of the ENDURANCE extension study. Br J Ophthalmol.
`2018 May;102(5):631‐636. PubMed PMID: 28814412.
`‐Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, Noronha G; Tanzanite Study Group.
`Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study. Ophthalmol Retina. 2018
`Apr;2(4):320‐328. PMID: 31047241.
`‐Brown DM, Heier JS, Boyer DS, Freund KB, Kaiser P, Kim JE, Sarraf D. . Current Best Clinical Practices—Management of
`Neovascular AMD J. VitreoRetinal Diseases. 2017 1(5) 294‐297.
`‐Kwon S, Wykoff CC, Brown DM, van Hemert J, Fan W, Sadda SR. Changes in retinal ischaemic index correlate with recalcitrant
`macular oedema in retinal vein occlusion: WAVE study. Br J Ophthalmol. 2018 Apr 26. pii: bjophthalmol‐2017‐
`311475.PubMed PMID: 29699979.
`‐Wykoff CC, Ou WC, Croft DE, Payne JF, Brown DM, Clark WL, Abdelfattah NS, Sadda SR; TREX‐AMD Study Group. Neovascular
`age‐related macular degeneration management in the third year: final results from the TREX‐AMD randomised trial. Br J
`Ophthalmol. 2018 Apr;102(4):460‐464. PubMed PMID: 28779006.
`‐Brown DM, Wykoff CC. Intravitreal aflibercept for proliferative diabetic retinopathy. Lancet. 2017 Nov 11;390(10108):2141.
`PubMed PMID: 29143753.
`‐Fan W, Wang K, Ghasemi Falavarjani K, Sagong M, Uji A, Ip M, Wykoff CC, Brown DM, van Hemert J, Sadda SR. Distribution
`of Nonperfusion Area on Ultra‐Widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. Am J
`Ophthalmol. 2017 Aug; 180:110‐116. PubMed PMID: 28579062.
`‐Jackson TL, Boyer DS, Brown DM,Chaudhry N, Elman M, Liang C, O’Shaughnessy D, Parsons E, Patel S, Slakter JS, Rosenfeld
`PJ. Oral tyrosine kinase inhibitor for neovascular age‐related macular degeneration: a phase 1 Dose Escalation Study. JAMA
`Opthalmology‐ 2017 Jul 1;135(7):761‐767. PubMed PMID: 28570723.
`‐Wykoff CC, Ou WC, Wang R, Brown DM, Cone C, Zamora D, Le RT, Sagong M, Wang K, Sadda SR; WAVE Study Group.
`Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. Ophthalmology. 2017
`Jun;124(6):919‐921. PMID: 28318636.
`‐Ou WC, Brown DM, Payne JF, Wykoff CC. Relationship Between Visual Acuity and Retinal Thickness During Anti‐Vascular
`Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol. 2017 May 23. pii: S0002‐9394(17)30216‐7. PMID:
`28549848.
`‐Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, Wang R, Clark WL, Boyer DS; ENDURANCE Study Group. Reply. Am J
`Ophthalmol. 2017 May; 177:236‐237. PubMed PMID: 28302270.
`‐Ho AC, Albini TA, Brown DM, Boyer DS, Regillo CD, Heier JS. The Potential Importance of Detection of Neovascular Age‐
`Related Macular Degeneration When Visual Acuity Is Relatively Good. JAMA Ophthalmol. 2017 Mar 1;135(3):268‐273. PMID:
`28114653.
`‐ Wykoff CC, Le RT, Khurana RN, Brown DM, Ou WC, Wang R, Clark WL, Boyer DS; ENDURANCE Study Group. Outcomes With
`As‐Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12‐Month Extension Study.
`Am J Ophthalmol. 2017 Jan; 173:56‐63. PMID: 27702624.
`‐Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM; TREX‐DME Study Group. Randomized Trial of Treat and
`Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX‐DME 1 Year Outcomes.
`Ophthalmology. 2017 Jan;124(1):74‐81. PMID: 27836430.
`‐Wang R, Wykoff CC, Brown DM. Granular Hyper‐reflective Specks by Spectral Domain Optical Coherence Tomography as a
`sign of West Nile Virus infection: The Stardust Sign Retin Cases Brief Rep. 2016 Fall;10(4):349‐53. PMID: 26674277.
`
`David M. Brown MD FACS
`Page 8
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 8
`
`
`
`‐Heier JS, Korobelnik JF, Brown DM, Schmidt‐Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen
`QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG. Intravitreal Aflibercept
`for Diabetic Macular Edema: 148‐Week Results from the VISTA and VIVID Studies. Ophthalmology. 2016 Nov;123(11):2376‐
`2385. PMID: 27651226.
`‐Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y,
`Campochiaro PA. Reply. Ophthalmology. 2016 Oct;123(10): e60‐1. PubMed PMID: 27664917.
`‐ Wang R, Wykoff CC, Christie L, Croft DE, Major JC Jr, Fish RH, Brown DM.Choroidal Neovascularization Secondary to
`Alexandrite Laser Exposure. Retina Cases Brief Rep. 2016 Summer;10(3):244‐8. PMID: 26584328.
`‐Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y,
`Campochiaro PA. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52‐Week Results of the
`VIBRANT Study. Ophthalmology. 2016 Feb;123(2):330‐6. Epub 2015 Oct 30. PMID: 26522708.
`‐Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack
`JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA 3rd; American Society of Retina Specialists Anti‐VEGF for Diabetic Macular
`Edema Comparative Effectiveness Panel. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of
`Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. JAMA Ophthalmol. 2016 Jan 1;134(1):95‐9. PMID:
`26512939.
`‐Wang R, Wykoff CC, Brown DM. Granular Hyperreflective Specks by Spectral Domain Optical Coherence Tomography as Signs
`of West Nile Virus Infection: The Stardust Sign. Retina Cases Brief Rep. 2015 Dec 13. PMID: 26674277.
`‐Li AL, Wykoff CC, Wang R, Chen E, Benz MS, Fish RH, Wong TP, Major JC Jr, Brown DM, Schefler AC, Kim RY, OʼMalley RE.
`Endophthalmitis after Intravitreal Injection‐: Role of Prophylactic Topical Ophthalmic Antibiotics. Retina. 2015 Dec 11. PMID:
`26655622.
`‐Major JC Jr, Wykoff CC, Croft DE, Wang R, Mariani AF, Lehmann AE, Brown DM. Aflibercept for pigment epithelial detachment
`for previously treated neovascular age‐related macular degeneration. Can J Ophthalmol. 2015 Oct;50(5):373‐7. Epub 2015
`Aug 12. PMID: 26455973.
`‐Boyer DS, Nguyen QD, Brown DM, Basu K, Ehrlich JS; RIDE and RISE Research Group. Outcomes with As‐Needed Ranibizumab
`after Initial Monthly Therapy: Long‐Term Outcomes of the Phase III RIDE and RISE Trials. Ophthalmology. 2015
`Dec;122(12):2504‐2513. Epub 2015 Oct 9. PMID: 26452713.
`‐Brown DM, Wykoff CC, Croft DE, Wong TP; RAVE Study Group. Reply: To PMID 24914476. Retina. 2015 Oct;35(10): e61‐3
`PMID: 26398558.
`‐Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR; TREX‐AMD Study Group. Prospective
`Trial of Treat‐and‐Extend versus Monthly Dosing for Neovascular Age‐Related Macular Degeneration: TREX‐AMD 1‐Year
`Results. Ophthalmology. 2015 Dec;122(12):2514‐22. Epub 2015 Sep 29. PMID: 26391465.
`‐Brown DM, Schmidt‐Erfurth U, Do DV, Holz FG, Boyer DS, Midena E, Heier JS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD,
`Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Korobelnik
`JF. Intravitreal Aflibercept for Diabetic Macular Edema: 100‐Week Results From the VISTA and VIVID Studies. Ophthalmology.
`2015 Oct;122(10):2044‐52. Epub 2015 Jul 18. PMID: 26198808.
`‐Croft DE, Wykoff CC, van Hemert J, Verhoek M, Brown DM. Not All Retina Is Created Equal: Metabolic Quantification of Ultra‐
`Widefield Images. Ophthalmology. 2015 Dec;122(12):2580‐2. Epub 2015 Jun 26. PMID: 26123089.
`‐Brown DM, Korobelnik JF; VISTA and VIVID study investigators. Intravitreal aflibercept for diabetic macular edema.
`Ophthalmology. 2015 Jun;122(6):e38‐9. PMID: 26008916.
`‐Wykoff CC, Brown DM, Croft DE, Major JC Jr, Wong TP. Progressive Non‐Perfusion in Ischemic Central Retinal Vein Occlusion.
`RETINA. 2015 Jan; 35(1): 43‐7. PMID: 25102193.
`
`David M. Brown MD FACS
`Page 9
`
`Samsung et al. v. Regeneron IPR2023-00884
`Regeneron Pharmaceuticals, Inc. Exhibit 2081 Page 9
`
`
`
`‐Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, Kazmi H, Berliner AJ, Erickson K, Chu KW, Soo Y, Cheng Y,
`Haller JA. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24‐Week Results of the
`VIBRANT Study. Ophthalmology. 2015 Mar;122(3):538‐44. PMID: 25315663.
`‐Brown DM. Eight Questions with Dr. Puliafito. Ophthalmic Surg Lasers Imaging Retina. 2014 Jul 1;45(4):353‐5. PMID:
`25037016.
`‐Croft DE, van Hemert J, Wykoff CC, Clifton D, Verhoek M, Fleming A, Brown DM. Precise montaging and metric quantification
`of retinal surface area from ultra‐widefield fundus photography and fluorescein angiography. Ophthalmic Surg Lasers
`Imaging Retina. 2014 Jul‐Aug 1;45(4):312‐7. PMID: 25037013.
`‐Korobelnik J‐F, Do DV, Schmidt‐Erfurth U, Boyer DS, Holz FJ, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen
`NJ, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl NS